A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours

British Journal of Cancer

Volumn 98, Issue 11, 2008, Pages 1762-1768

  Contreras Hernandez I ^a   Mould Quevedo, J F ^b   Silva, A ^a   Salinas Escudero, G ^a   Villasis Keever M A ^c   Granados Garcia V ^a   Davila Loaiza G ^b   Petersen, J A ^b   Garduo Espinosa J ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b PFIZER INC   (United States)

^c HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

Cost effectiveness analysis; Gastrointestinal stromal tumours; Imatinib; Markov models; Sunitinib

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HEALTH CENTER; HEALTH INSURANCE; HUMAN; INTERVENTION STUDY; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HEALTH CARE COSTS; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; PYRROLES;

EID: 44349180836     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604367     Document Type: Article

References (26)

1. Alvarado-Cabrero I, Vazquez G, Sierra Santiesteban FI, Hernandez-Hernandez DM, Pompa AZ (2007) Clinico-pathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico. Ann Diagn Pathol 11: 39-45
2. Badalamenti G, Rodolico V, Fulfaro F, Cascio S, Cipolla C, Cicero G, Incorvaia L, Sanfilippo M, Intrivici C, Sandonato L, Pastuso G, Latteri MA, Gebbia N, Russo A (2007) Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol 18(suppl. 6): vi136-vi140 doi:10.1093/annonc/mdm243
3. Blanke CD, Corless CL (2005) State of the art therapy for gastrointestinal stromal tumors. Cancer Invest 23: 274-280
4. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PCW, Joensuu H, Le Cesne A, Mac Clure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants A, van Glabbeke M, van Oosterom A, Demetri GD (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16: 566-578
5. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038
6. Dematteo RP, Heinrich M, CEL-Rifai WM, Demtri G (2002) Clinical management of gastrointestinal stromal tumors, before and after STI-571. Human Pathol 33: 466-477
7. Demetri GD, Van Oosterom A, Garrett C (2005) Sunitinib malate (SU 11248) prolongs progression-free and overall survival for GIST patients after failure of imatinib mesylate therapy: update of a phase III trial. Eur J Cancer 3(suppl): 203
8. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet 368: 1329-1338
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumor. N Engl J Med 347: 472-480
10. Emory TS, Sobón LH, Lukes L, Lee DH, O'Leary TJ (1999) Prognosis of gastrointestinal smooth muscle (stromal) tumors dependence on anatomic site. Am J Surg Pathol 23: 82-87
11. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley J, Miettinen M, O'leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465
12. Hassan I, You N, Dozois EJ, Shayyan R, Smyrk TC, Okuno SH, Donohue JH (2006) Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 49: 609-615
13. Hirota S, Isozaki K (2006) Pathology of gastrointestinal stromal tumors. Pathol Int 56: 1-9
14. Hornick JL, Fletcher CDM (2007) The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38: 679-687
15. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056
16. Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30: 477-489
17. Motzer RJ, Hoosen S, Bello CL, Christensen JG (2006) Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 15: 553-561
18. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, version 2.2006 (2006)
19. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K (2003) Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33: 533-537
20. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202: 623-629
21. Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumor. Lancet 369: 1731-1741
22. Smith D, Gravelle H. The practice of discounting economic evaluation of health care interventions. Center for Health Economics Technical Paper Series 19. University of York: October (2000)
23. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR (2005) Initial an late resistant to imatinib in advanced gastrointestinal stromal tumors are predicted be different prognostic factors. A European Organisation for Research and Treatment of Cancer. Italian Sarcoma Group - Australasian Gastrointestinal Trials Group Study. J Clin Oncol 23: 5795-5804
24. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127-1134
25. Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saijo N (2003) Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 94: 1015-1020
26. Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D (2005) Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 9: 1-142